Retained Earnings (Accumulated Deficit) of Acrivon Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Acrivon Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • Acrivon Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Sep 2025 was $255,896,000, a 47% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

Acrivon Therapeutics, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $255,896,000 -$81,751,000 -47% 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $237,662,000 -$85,958,000 -57% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $216,656,000 -$83,750,000 -63% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $196,976,000 -$80,556,000 -69% 31 Dec 2024 10-Q 13 Nov 2025 2025 Q3
Q3 2024 $174,145,000 -$76,977,000 -79% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $151,704,000 -$69,002,000 -83% 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $132,906,000 -$16,506,000 -14% 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $116,420,000 -$60,388,000 -108% 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $97,168,000 -$50,065,000 -106% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $82,702,000 30 Jun 2023 10-Q 11 Aug 2023 2023 Q2
Q1 2023 $116,400,000 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $56,032,000 -$31,167,000 -125% 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $47,103,000 30 Sep 2022 10-Q 15 Dec 2022 2022 Q3
Q4 2021 $24,865,000 31 Dec 2021 10-K 28 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.